


Bisindolylmaleimide III

Cat. No.:	HY-117393		
CAS No.:	137592-43-9		
Molecular Formula:	C ₂₃ H ₂₀ N ₄ O ₂		
Molecular Weight:	384.43		
Target:	PKC		
Pathway:	Epigenetics; TGF-beta/Smad		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (65.03 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6013 mL	13.0063 mL	26.0125 mL
		5 mM	0.5203 mL	2.6013 mL	5.2025 mL
10 mM		0.2601 mL	1.3006 mL	2.6013 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (3.25 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.25 mg/mL (3.25 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Bisindolylmaleimide III is a potent and selective inhibitor of protein kinase C (PKC). Bisindolylmaleimide III selectively interacts with either PKCα or ribosomal S6 protein kinase 1 after activation of these kinases ^[1] .
IC ₅₀ & Target	PKCα

REFERENCES

[1]. Brehmer D, et al. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics. 2004 May;3(5):490-500.

[2]. Saito Y, et, al. Role of ecto-kinase in phorbol ester-enhanced growth hormone-binding protein release from human IM-9 cells. Mol Cell Endocrinol. 1999 Jun 25;152(1-2):65-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA